Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein

Nelson, 2010, Development trends for human monoclonal antibody therapeutics, Nat. Rev. Drug Discov., 9, 767, 10.1038/nrd3229 Logtenberg, 2007, Antibody cocktails: next-generation biopharmaceuticals with improved potency, Trends Biotechnol., 25, 390, 10.1016/j.tibtech.2007.07.005 Bakker, 2008, First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity, Vaccine, 26, 5922, 10.1016/j.vaccine.2008.08.050 Prabakaran, 2009, Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants, PLoS One, 4, e5672, 10.1371/journal.pone.0005672 Chen, 2009, Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody, Infect. Immun., 77, 3902, 10.1128/IAI.00200-09 Mazor, 2010, Combination of anthrax–toxin neutralizing antibodies: analysis of synergism/antagonism effect, 275 Pedersen, 2010, Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy, Cancer Res., 70, 588, 10.1158/0008-5472.CAN-09-1417 European Commission, Production and quality control of monoclonal antibodies, directive 75/318/EEC3AB4a, Committee for Medicinal Products for Human Use, 1995. US Department of Health and Human Services, Points to consider in the manufacture and testing of monoclonal antibody products for human use, Food and Drug Administration, Center for Biologics Evaluation and Research, 1997. Schenerman, 2004, CMC strategy forum report: analysis and structure characterization of monoclonal antibodies, BioProcess Int., 2, 42 Arnon, 2001, Botulinum toxin as a biological weapon: medical and public health management, JAMA, 285, 1059, 10.1001/jama.285.8.1059 St. John, 2001, Bioterrorism in Canada: an economic assessment of prevention and postattack response, Can. J. Infect. Dis., 12, 275, 10.1155/2001/904148 Black, 1980, Hypersensitivity reactions associated with botulinal antitoxin, Am. J. Med., 69, 567, 10.1016/0002-9343(80)90469-6 Hibbs, 1996, Experience with the use of an investigational F(ab′)2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt, Clin. Infect. Dis., 23, 337, 10.1093/clinids/23.2.337 Nowakowski, 2002, Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody, Proc. Natl. Acad. Sci. USA, 99, 11346, 10.1073/pnas.172229899 Blasco, 2007, Evaluation of a peptide ELISA for the detection of rituximab in serum, J. Immunol. Methods, 325, 127, 10.1016/j.jim.2007.06.011 Damen, 2009, Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma, Anal. Biochem., 391, 114, 10.1016/j.ab.2009.05.030 Tornetta, 2007, Isolation of human anti-idiotypic antibodies by phage display for clinical immune response assays, J. Immunol. Methods, 328, 34, 10.1016/j.jim.2007.08.008 Meng, 2012, Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein, Anal. Biochem., 421, 351, 10.1016/j.ab.2011.09.030 Gilsdorf, 2006, Expression, purification, and characterization of Clostridium botulinum type B light chain, Protein Expr. Purif., 46, 256, 10.1016/j.pep.2005.09.024 Levy, 2007, Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display, J. Mol. Biol., 365, 196, 10.1016/j.jmb.2006.09.084 Blake, 1999, Automated kinetic exclusion assays to quantify protein binding interactions in homogeneous solution, Anal. Biochem., 272, 123, 10.1006/abio.1999.4176 Lou, 2010, Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating, Protein Eng. Des. Sel., 23, 311, 10.1093/protein/gzq001 Razai, 2005, Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A, J. Mol. Biol., 351, 158, 10.1016/j.jmb.2005.06.003 Szutowicz, 1984, Colorimetric assay for monoamine oxidase in tissues using peroxidase and 2,2’-azinodi(3-ethylbenzthiazoline-6-sulfonic acid) as chromogen, Anal. Biochem., 138, 86, 10.1016/0003-2697(84)90773-5 Engvall, 1980, Enzyme immunoassay ELISA and EMIT, Methods Enzymol., 70, 419, 10.1016/S0076-6879(80)70067-8 Al-Kaissi, 1983, Assessment of substrates for horseradish peroxidase in enzyme immunoassay, J. Immunol. Methods, 58, 127, 10.1016/0022-1759(83)90269-7 Eswaramoorthy, 2004, Role of metals in the biological activity of Clostridium botulinum neurotoxins, Biochemistry, 43, 2209, 10.1021/bi035844k Kumaran, 2009, Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation, J. Mol. Biol., 386, 233, 10.1016/j.jmb.2008.12.027 Tang, 2007, Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen, J. Immunol., 179, 2815, 10.4049/jimmunol.179.5.2815 Lacy, 1998, Crystal structure of botulinum neurotoxin type A and implications for toxicity, Nat. Struct. Biol., 5, 898, 10.1038/2338